jefferies 2018

The Jefferies Global Healthcare 2018 Presentation can be watched here.

Dune Medical Devices strives to improve the standard of care for cancer patients every single day. With a first indication in breast cancer, our proprietary radiofrequency spectroscopy platform has been utilized in over 10,000 patients. Our first device, MarginProbe®, has been shown to reduce re-excision rates in lumpectomy surgery by 62%.

And we are not stopping there. Our RF platform based biopsy device is currently in development thanks in part to a $3 million EC Horizon 2020 grant.

If you would like to know more about our business and its potential, contact

01Aug 18

New Research Shows MarginProbe® Reduces Re-Excision Rates for Breast Conserving Surgery by 61%, Giving Renewed Hope to Breast Cancer Patients

A study recently published in the American Journal of Surgery demonstrates that proper use of Dune Medical Devices’ intraoperative margin assessment device, MarginProbe, results in a significant identification of positive margins and a resulting reduction in the re-excision rate for breast conserving surgery - the standard option for patients with early-stage breast cancer.
read more